Pembroria

    imagePackage photo coming soon
    file_download Patient leaflet

    info General information

    Name Pembroria, 25 mg/mL, concentrate for solution for infusion
    INN Pembrolizumab
    Active substance Pembrolizumab
    Pharmacotherapeutic group Antineoplastic agents. Monoclonal antibodies and antibody-drug conjugates. PD-1/PD-L1 (programmed cell death protein 1/ligand 1) inhibitors. Pembrolizumab
    Dosage form Concentrate for solution for infusion
    Packaging

    4 mL of the product in vials. 1 vial is placed in a cardboard box, or 1 vial in a blister pack is placed in a cardboard box.

    Manufacturer Karaganda Pharmaceutical Complex LLP EU GMP

    assignment_turned_in Indications

    • Melanoma (a type of skin cancer);
    • Non-small cell lung cancer;
    • Squamous cell carcinoma of the head and neck;
    • Classical Hodgkin lymphoma;
    • Urothelial carcinoma (a type of cancer of the urinary tract);
    • Esophageal cancer;
    • Malignant tumors with high microsatellite instability (MSI-H) or DNA mismatch repair deficiency (dMMR) (certain tumor cell properties detected by special tests);
    • Colorectal cancer (a type of cancer of the large intestine);
    • Cervical cancer;
    • Renal cell carcinoma;
    • Endometrial cancer (a type of uterine cancer);
    • Triple-negative breast cancer;
    • Adenocarcinoma of the stomach or gastroesophageal junction;
    • Biliary tract carcinoma.